Detalles de la búsqueda
1.
Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
Pharmacology
; 82(2): 156-63, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18679040
2.
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Adv Ther
; 25(8): 752-74, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18704282
3.
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.
Clinicoecon Outcomes Res
; 7: 95-103, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25674008
4.
Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Eur J Health Econ
; 15(1): 69-82, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23392624
5.
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Int J Chron Obstruct Pulmon Dis
; 7: 183-99, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22500119
6.
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
Curr Med Res Opin
; 24(5): 1417-28, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18400145
Resultados
1 -
6
de 6
1
Próxima >
>>